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Abstract
Brucellosis is a widespread zoonotic disease that is also a potential agent of bioterrorism. Current serological assays to
diagnose human brucellosis in clinical settings are based on detection of agglutinating anti-LPS antibodies. To better
understand the universe of antibody responses that develop after B. melitensis infection, a protein microarray was fabricated
containing 1,406 predicted B. melitensis proteins. The array was probed with sera from experimentally infected goats and
naturally infected humans from an endemic region in Peru. The assay identified 18 antigens differentially recognized by
infected and non-infected goats, and 13 serodiagnostic antigens that differentiate human patients proven to have acute
brucellosis from syndromically similar patients. There were 31 cross-reactive antigens in healthy goats and 20 cross-reactive
antigens in healthy humans. Only two of the serodiagnostic antigens and eight of the cross-reactive antigens overlap
between humans and goats. Based on these results, a nitrocellulose line blot containing the human serodiagnostic antigens
was fabricated and applied in a simple assay that validated the accuracy of the protein microarray results in the diagnosis of
humans. These data demonstrate that an experimentally infected natural reservoir host produces a fundamentally different
immune response than a naturally infected accidental human host.
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Introduction
Brucellosis is a zoonotic infectious disease endemic in regions
around the world where agricultural, animal husbandry and
vaccination practices have not controlled infection among
livestock reservoirs [1–3]. The reservoirs of Brucella melitensis, the
most virulent species affecting humans, include goats and sheep
[4], especially in Peru and the Middle East [3]. Identification of
goat, sheep and other animal sources of infection have long used
agglutination tests, although newer tests are being developed and
applied in the veterinary setting [5–7]. Commonly used screening
tests do not necessarily differentiate between vaccination and
infection in goats ([8]; summarized in [6]). By themselves, the
Rose Bengal and other agglutination tests cannot be used
exclusively to diagnose human brucellosis because while sensitive
and specific for first episodes of brucellosis, these tests can be
problematic in differentiating acute, chronic and relapsing forms
of brucellosis in humans living in endemic regions [9–12], and
typically require titration and differentiation of IgM from IgG
antibodies either in solid phase formats or by use of the
mercaptoethanol test [1,3,13–16].
The current knowledge of protein antigens recognized by
humans and reservoir animals is limited to a relatively small
number of immunogenic Brucella abortus proteins recognized by
cattle, mice and sheep and limited studies on human and goat
recognition of Brucella melitensis antigens [9–11,17–33]. No
individual antigen has proven to be of sufficient diagnostic
utility to replace the LPS-based tests. Indeed, antibodies to
smooth LPS have been observed to arise sooner in the course
of brucellosis compared to known antigens or groups of
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uncharacterized cytoplasmic protein antigens [15,34–43], espe-
cially if treatment is initiated early after clinical presentation
[43]. We tested the hypothesis that the immune response to B.
melitensis infection of natural reservoir host (goat) and accidental
host (humans) is similar despite potentially different routes of
infection. For this we constructed a protein microarray
consisting of 1406 B. melitensis proteins and probed with a
collection of sera from naturally infected and control human
sera from Lima Peru, and goats experimentally infected with
virulent B. melitensis 16M.
Materials and Methods
Ethics statement
Human sera were obtained from patients enrolled in a
prospective clinical study of brucellosis in Lima, Peru. The human
subjects part of the study was approved by the Humans Research
Protections Committee of the University of California San Diego,
the Comite de E´tica of Universidad Peruana Cayetano Heredia,
Lima, Peru and the Comite de E´tica of Asociacio´n Bene´fica
PRISMA, Lima, Peru, all of whom have maintained federal wide
assurances with the United States Department of Health and
Human Services. All patients provided written informed consent
prior to enrollment in the study, and signed consent forms have
been stored in locked files in study offices at UPCH and AB
PRISMA, Lima, Peru.
Goat sera were obtained from previously stored samples from
experimentally infected goats under Institutional Animal Care and
Use protocols approved by Texas A&M University, College
Station, Texas, USA. Animals were housed in an outdoor,
restricted access, large-animal isolation facility operated under
guidelines approved by the United States Department of
Agriculture/Animal and Plant Health Inspection Service
(USDA/APHIS). At the termination of the experiments, adult
animals were euthanized by captive bolt. All animals were
disposed of by University approved protocols.
Gene amplification and cloning
Genes were amplified and cloned using high-throughput PCR
and recombination method as described previously [44]. ORFs
from Brucella melitensis 16M genomic DNA were identified using
GenBank NC_003317 and NC_003318, amplified using gene
specific primers containing 33bp nucleotide extension comple-
mentary to ends of linearized pXT7 vector. Homologous
recombination takes place between the PCR product and pXT7
vector in competent DH5a cells. The recombinant plasmids were
isolated from this culture using QIAprep 96 Turbo kit (Qiagen).
Around one quarter of the cloned genes were sequenced and
verified that the correct sequence was inserted. The resulting
fusion proteins also harbor a hemagglutinin epitope at 39 end and
polyhistidine at the 59 end.
Microarray printing and staining
Plasmids were expressed at 30uC in 5 hour- in vitro transcrip-
tion/translation E. coli system (RTS 100 kits from Roche),
according to the manufacturer’s instructions. For microarrays,
15 ml of reaction was mixed with 5 ml 0.2% Tween 20 to give a
final concentration of 0.05% Tween 20, and 15-ml volumes were
transferred to 384-well plates and printed onto nitrocellulose
coated glass FAST slides (Whatman) using Omni Grid 100
microarray printer (Genomic Solutions). Protein expression and
printing was monitored by immunoprobing with anti-polyhistidine
(clone His-1, Sigma) and anti-hemagglutinin (clone 3F10, Roche).
For all array staining, sera samples were diluted to 1:200 in Protein
Array Blocking Buffer (Schleicher & Schuell). Slides were first
blocked for 30 min in protein array-blocking buffer before
incubation with primary antibody at 4uC overnight with agitation.
The slides are then washed extensively and incubated in biotin-
conjugated secondary antibody (Jackson Immuno Research)
diluted 1/200 in blocking buffer. After washing, bound antibodies
are detected by incubation with streptavidin-conjugated Sure-
LightH P-3 (Columbia Biosciences). The slides are washed and air
dried after brief centrifugation. Slides were scanned and analyzed
using a Perkin Elmer ScanArray Express HT microarray scanner.
Intensities are quantified using QuantArray software. All signal
intensities are corrected for spot-specific background.
Brucella melitensis serum samples
Human sera tested in this study were obtained from the following
patient groups: patients confirmed (by positive blood culture) to have
acute brucellosis in Lima, Peru; from culture-negative, Rose Bengal-
positive patients presenting with brucellosis-compatible syndromes;
Rose Bengal-negative patients referred by their physicians for
possible brucellosis; and ambulatory, apparently healthy control
patients from the north Lima neighborhood of Puente Piedra where
brucellosis is known to occur with risk factors similar to those in the
rest of Lima. No patients in this study were known to be directly
exposed to goats; risk factors for all were reported to be ingestion of
unpasteurized goat’s milk products, the typical risk factor in Lima
for acquisition of brucellosis. All patients included in this study had
their first known episode of brucellosis, with clinical presentation
within 1–3 weeks of onset of symptoms. The patient samples were as
follows: 42 serum samples from B. melitenis culture-positive patients all
of whom were positive by the Rose Bengal screening test and had
tube agglutination tests .= 1/160; and 18 samples from culture
negative, Rose Bengal serology-positive patients. These latter 18
samples were from culture negative individuals diagnosed with
brucellosis and treated according to standard antibiotic therapy
within 2 days of serum sampling. Additional control patient samples
included 13 sera from Rose Bengal-negative patients, 44 samples
from ambulatory healthy controls from north Lima where
Author Summary
Brucellosis is a bacterial disease transmitted from infected
animals to humans. This disease often presents as a
prolonged but non-specific illness primarily characterized
as fever without specific organ localization. Because
infections can result after ingestion (typically from
unpasteurized animal milk or milk products from goats,
cattle or sheep) or inhalation (important because of
bioterrorism potential) of small numbers of organisms,
the bacteria that cause brucellosis are potential biological
warfare agents. Here, a protein microarray containing 1406
Brucella melitensis proteins was used to study the antibody
response of experimentally infected goats and naturally
infected humans in B. melitensis infection. Goats recog-
nized 18 proteins and humans recognized 13 proteins as
serodiagnostic antigens; antibody detection of only two of
these antigens was shared by goats and humans,
suggesting either fundamentally different immune re-
sponses or different responses in relation to mode or
setting of infection. The human serodiagnostic antigens
were evaluated in a simple nitrocellulose line blot assay,
which validated the protein microarray results. The
approach described here will lead to the development of
new diagnostics for brucellosis and other infectious
diseases, and aid in understanding the human and animal
host immune response to pathogenic organisms.
B. melitensis Immune Response in Humans and Goats
www.plosntds.org 2 May 2010 | Volume 4 | Issue 5 | e673
brucellosis occasionally affects patients, and sera from humans in the
U.S. where brucellosis is not found.
Goat sera tested in this study were positive (B. melitensis 16M-
infected) and negative (uninfected) controls from a previously
conducted vaccine safety study [23] in which pregnant, card-test
negative angora goats were inoculated with B. melitensis. Goats
were experimentally infected with 16107 CFU of Brucella melitensis
strain 16M by bilateral conjunctival instillation at 110 days’
gestation, and sera were collected 8 weeks after infection. As an
additional negative control, 15 serum samples from a specific
pathogen-free goat flock were obtained (Capralogics, Inc, Hard-
wick, MA).
Immunostrip printing and probing
Thirteen plasmids of interest were expressed in five hour in vitro
transcription-translation reactions (RTS 100 E. coli HY Kit from
Roche) according to the manufacturer’s instructions. VIG was
obtained from ADi as a gift, and the concentration of VIG was
diluted to 0.05 mg/ml. Proteins were printed on Optitran BA-S 85
0.45 mm Nitrocellulose membrane (Whatman) using BioJet
dispenser (BioDot) at 1 ml/cm, and cut into 3 mm strips.
Individual strips were then blocked in 10% non fat dry milk
dissolved in 10 mM Tris (pH 8.0) and 150 mM NaCl containing
0.05% (v/v) Tween 20 buffer for 30 minutes. Prior to immuno-
strip probing, forty two culture positive and forty four Peruvian
naive sera were diluted to 1/250 in 10% non fat dry milk solution
containing 20% E. coli lysate (McLab) and incubated for
30 minutes with constant mixing at room temperature. Each strip
was then incubated with pretreated sera overnight at 4uC with
gentle mixing. Strips were then washed five times in Tris buffer
containing 0.05% (v/v) tween 20, and then incubated for 1 hour
at room temperature in alkaline phosphatase conjugated donkey
anti-human immunoglobulin (anti-IgG, Fcc fragment-specific,
Jackson ImmunoResearch), diluted to 1/5000 in tris buffer
containing 0.05% (v/v) tween 20. Strips were then washed
extensively and reactive bands were visualized by incubating with
1-step Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-39-
Indolyphosphate p-Toluidine Salt (NBT/BCIP) developing buffer
(Thermo Fisher Scientific) for 1 minute at room temperature.
Strips were scanned with Hewlett-Packard scanner, and were
quantified using Image J software.
Data analysis
All analysis was performed using the R statistical environment
(http://www.r-project.org). It has been noted in the literature that
data derived from microarray platforms is heteroskedatic [45–48].
This mean-variance dependence has been observed in the arrays
presented in this manuscript [49,50]. In order to stabilize the
variance, the vsn method [51] implemented as part of the
Bioconductor suite (www.bioconductor.org) is applied to the
quantified array intensities. In addition to removing heteroskeda-
city, this procedure corrects for non-specific noise effects by
finding maximum likelihood shifting and scaling parameters for
each array such that control probe variance is minimized. This
calibration has been shown to be effective on a number of
platforms [52–54]. Normalized data is retransformed with the
‘sinh’ function to allow visualization and discussion at an
approximate raw scale.
Diagnostic biomarkers between groups were determined using a
Bayes regularized t-test adapted from Cyber-T for protein arrays
[47,48], which has been shown to be more effective than other
differential expression techniques [55]. To account for multiple
testing conditions, the Benjamini and Hochberg (BH) method was
used to control the false discovery rate [56]. Multiplex classifiers
were constructed using linear and non-linear Support Vector
Machines (SVMs) using the ‘‘e1071’’ R package. SVM is a
supervised learning method that has been successfully applied to
microarray data characterized by small samples sizes and a large
number of attributes [50,57]. The SVM approach, as any other
supervised classification approach, uses a training dataset to build
a classification model and a testing set to validate the model. To
generate unbiased training and testing sets, leave one out cross-
validation (LOOCV) was used. With this methodology, each data
point is tested with a classifier trained using all of the remaining
data points. Plots of receiver operating characteristic (ROC) curves
were made with the ‘ROCR’’ R package.
Results
Gene amplification, cloning and protein expression
A set of 1406 ORFs from Brucella melitensis 16M was selected for
this study. We picked 1009 antigens based on their Psort
information and B cell epitope prediction score, and 397 ORFs
were randomly selected. The ORFs were amplified from Brucella
melitensis 16M (Bm) genomic DNA and cloned using the high
Figure 1. Construction of a B. melitensis Protein Microarray.
Arrays were printed containing 1406 B. melitensis proteins, positive and
negative control spots. Proteins were printed in duplicates. Each array
contains positive control spots printed from 6 serial dilutions of human
and mouse IgG, 6 serial dilutions of EBNA1 protein, and ‘‘No DNA’’
negative control spots. (A) The array was probed with anti-His antibody
as described in Materials and Methods, to confirm the expression and
printing of over 95% proteins. (B) Comparison of arrays probed with
Peruvian naı¨ve serum and Culture positive serum. The arrays were read
in a laser confocal scanner, analyzed, and the data normalized as
described in Materials and Methods. The signal intensity of each
antigen is represented by rainbow palette of blue, green, red and white
by increasing signal intensity.
doi:10.1371/journal.pntd.0000673.g001
B. melitensis Immune Response in Humans and Goats
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throughput recombination method previously described [44].
About one-fourth of the cloned genes were sequenced and
.99% of sequenced clones had the correct sequence in frame
with correct orientation. Bm ORFs cloned in pXT7 vector were
expressed under T7 promoter in the E. coli in vitro transcription/
translation system, and printed in duplicates on microarrays as
described in Methods and 97.4% of the proteins were positive for
the His tag (Fig. 1a), and 95.4% were positive for HA tags.
Immune screening with goat serum samples
Bm protein arrays were probed with sera from experimentally
infected goats, naı¨ve goats from the same pasture, and specific
Figure 2. Probing a collection of B. melitensis infected, uninfected, and SPF control goat sera and discovery of goat serodiagnostic
antigens. Arrays containing 1406 B. melitensis proteins were probed with goat sera organized into 3 groups as described in the text. (A). Heatmap
showing normalized intensity with red strongest, bright green weakest and black in between. The antigens are in rows and are grouped to
serodiagnostic and cross-reactive antigens. The goat samples are in columns and sorted left to right by increasing average intensity to serodiagnostic
antigens. (B) The mean sera reactivity of the 1406 antigens was compared between the Infected and SPF Naive groups. Antigens with Benjamini
Hochberg corrected p-value less than 0.05 are organized to the left and cross-reactive antigens to the right. The 18 most reactive serodiagnostic and
31 of the most reactive cross-reactive antigens are shown.
doi:10.1371/journal.pntd.0000673.g002
B. melitensis Immune Response in Humans and Goats
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Figure 3. Probing a collection of B. melitensis human sera and discovery of human serodiagnostic antigens. Arrays were probed with
human sera organized into 5 groups: Culture Positive, Culture Negative/Rose Bengal Positive, Rose Bengal Negative, USA Naı¨ve, and Peruvian Naı¨ve,
as described in the text. (A). Heatmap showing normalized intensity with red strongest, bright green weakest and black in between. The antigens are
in rows and are grouped to serodiagnostic and cross-reactive antigens. The human samples are in columns and sorted left to right by increasing
average intensity to serodiagnostic antigens. (B) The mean sera reactivity of the 1406 antigens was compared between the Culture Positive and
Peruvian Naive groups. Antigens with Benjamini Hochberg corrected p-value less than 0.05 are organized to the left and cross-reactive antigens to
the right. The 13 most reactive serodiagnostic and 31 of the most reactive cross-reactive antigens are shown. C2/RB+, Culture Positive and Rose
Bengal negative; RB2, Rose Bengal negative. Numbers in () are case numbers from each group.
doi:10.1371/journal.pntd.0000673.g003
B. melitensis Immune Response in Humans and Goats
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pathogen free (SPF) goats from a different location. Reactivity of
sera from the individual goats is shown as a heat map with samples
grouped according to their description (Fig. 2a). Data were
analyzed using methods described elsewhere [58]. Serodominant
antigens are defined as antigens with mean signal intensity greater
than the mean plus two standard deviations above the negative
controls. Serodiagnostic antigens are significantly differentially
reactive serodominant antigens with adjusted Cyber-T p-values
between infected and SPF goats ,0.05. All of the sera, whether
from infected, uninfected or naı¨ve goats, reacted similarly to the
cross-reactive antigens (p-value .0.05). A set of 49 antigens were
identified to be serodominant among 1406 antigens tested. Of
these, 18 antigens were serodiagnostic, and reacted differentially
between infected goats and SPF goats (p-value ,0.05). The
remaining 31 serodominant antigens reacted similarly among all
goats (Fig. 2a, 2b).
Human antigenic profile
Bm protein arrays were also probed with sera from acute
brucellosis patients in Lima, Peru obtained within 1–3 weeks of
the onset of symptoms. All patients in this study, as is true of
virtually all patients from Lima [3,59–62], were infected with B..
melitensis biovar 1. Sera from Bm culture-positive humans (Fig. 1b)
showed pronounced reactivity against several antigens compared
to unexposed individuals. A set of 33 antigens was identified to be
serodominant among 1406 antigens tested (Fig. 3a, 3b). Of
these, 13 antigens were serodiagnostic, and reacted differentially
between naı¨ve and culture positive patients from Peru (p-
value,.05). The same antigens also reacted robustly with
individuals diagnosed Rose Bengal positive but negative by blood
culture for B. melitensis. For some of these subjects, treatment with
antibiotics may have resulted in a negative blood culture for B.
melitensis. The elevated antibody response from a few individuals
in the Peruvian naı¨ve group might be indicative of past exposure
to similar proteins in environmental bacteria, or to a past
subclinical Brucella infection. We also identified 20 cross-reactive
antigens that reacted similarly among all human samples,
whether from naı¨ve individuals or individuals diagnosed to be
infected and use of these antigens in serodiagnostic tests can
therefore be selectively avoided.
Identification of serodiagnostic antigens
To establish a collection of antigens able to accurately
distinguish brucellosis cases from controls, leave one out cross-
validation (LOOCV) receiver operating characteristic (ROC)
curves were generated for individual serodiagnostic antigens to
assess the ability to separate the control and disease cases (Fig. 4).
The serodiagnostic antigens were ordered by decreasing single
antigen area under the curve (AUC). The top ten ORFs all have
an AUC greater than 0.734 (Table 1), with BP26 (BMEI0536;
AUC 0.983; Benjamini and Hochberg adjusted Cyber-T p-
value,10e-16) giving the best single antigen discrimination with
sensitivity and specificity 91% and 96% (Fig. 4), respectively. We
used kernel methods and support vector machines [47,63] to build
linear and nonlinear classifiers. As input to the classifier, we used
the highest-ranking 1, 2, 5, 10, 13 ORFs on the basis of single
antigen AUC. The results show that increasing the antigen
number from 2 to 5 produced an improvement in sensitivity and
specificity (Fig. 4). This classifier yielded a high sensitivity and
specificity rate of 95% and 96%, respectively.
Validation of serodiagnostic accuracy with immunostrips
To test the feasibility of using the serodiagnostic antigens in an
alternative analytical assay, thirteen serodiagnostic proteins were
printed onto Nitrocellulose membranes using a BioDot jet
dispenser. The paper was then cut into 3 mm strips (Fig. 5a).
The individual strips were probed with 42 different culture positive
sera and 44 Peruvian naive sera. Brucellosis patients reacted
strongly against the serodiagnostic antigens with variable signal
intensity among the patients. Naı¨ve samples showed much lower
reactivity against these serodiagnostic antigens. To assess the
ability of antigens to separate disease and healthy controls, the
LOOCV ROC curve was also generated (Fig. 5b). The ROC
curve shows that this probing test yielded a high AUC of 0.962
with sensitivity rate of 94% and specificity rate of 89%. Thus,
thirteen differentially reactive serodiagnostic antigens identified by
microarray analysis in immunostrip format validated the list of
serodiagnostic antigens to correctly classify B. melitensis positive
sera.
The sensitivity and specificity of the top 5 serodiagnostic
antigens discovered using the protein microarrays had sensitivity
and specificity of 95% and 96%, better than that of the 13 antigens
on the immunostrips (94% and 89%).
Comparing antigenic proteins among humans and goats
Both humans and animals can be infected by Bm. In the present
study, goats were infected by B. melitensis strain 16M which would
be expected to be virtually identical to the strains infected by
patients in Lima given the limited diversity of the strains found
there [3,59–62]. To better understand the differences in the
immune response to Bm infection between humans and goats, we
compared serodominant antigens for both humans and goats. In
the current study, two antigens are found to be serodiagnostic for
both humans and goats (Fig. 6, Table 1). The top antigen on the
list, BMEI0536 (Bp26 protein) is a 26KD periplasmic immuno-
genic protein which was simultaneously identified by three
nonrelated research groups as an immunodominant antigen in
infected cattle, sheep, goats, and humans [17,19,27,35]. Use of an
Figure 4. Multiple Antigen LOOCV ROC curves. The LOOCV ROC
graphs show classifiers with increasing number of human serodiagnos-
tic antigens. Overall, the sensitivity and specificity for array test is over
95%.
doi:10.1371/journal.pntd.0000673.g004
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indirect ELISA to detect antibodies in brucellosis patients (n = 20)
and uninfected controls (n = 35) yielded a sensitivity of 0.9 and
specificity of 0.91 (not shown). Another serodiagnostic protein for
both humans and goats was Protease DO, also designated as HtrA
[31]. Use of an indirect ELISA to BMEI1330 yielded a sensitivity
of 0.84 and a specificity of 0.99. Thus, the ELISA data were
consistent with values determined using immunostrips and with
the proteome array data. There are 11 antigens exclusively useful
for human brucellosis diagnosis and 16 antigens exclusively for
goats. Most of these are membrane proteins, lipoproteins,
transporter proteins, proteins with signal peptide and proteins
related to pathogenicity. We also identified 8 common cross-
reactive antigens for both humans and goats, and 12 exclusively
for humans and 23 for goats (Fig. 6, Table 2).
Table 1. Common and specific Brucella melitensis antigens for humans and goats.
B. melitensis 16M B. abortus 2308 B. suis 1330 AUC Product Name
Reference for other
Brucella species
Serodiagnostic for
both Humans and
Goats
BMEI0536 BAB1_1494 BR1475 0.983 26 kDa periplasmic immunogenic
protein bp26
{Cloeckaert, 1996; Connolly,
2006; Lindler, 1996; Yang,
2005}
BMEI1330 BAB1_0635 BR0611 0.870 Protease Do {Roop, 1994}
Serodiagnostic for
Humans only
BMEI1439 BAB1_0522 BR0497 0.715 Chromosome Segregation
Protein SMC
BMEI0340 BAB1_1707 BR1695 0.889 Omp16 lipoprotein {Tibor, 1994}
BMEI0141 BAB1_1922 BR1922 0.734 2-oxoglutarate dehydrogenase,
E2 component, dihydro-
lipoamide succinyltransferase
BMEII0032 BAB2_0061 BRA0062 0.849 VirB8
BMEI0228 BAB1_1830 BR1822 0.719 Hypothetical protein
BMEI1890 BAB1_0051 BR0054 0.866 Transporter
BMEI0810 BAB1_1199 BR1177 0.918 COG1434 Uncharacterized
conserved protein
BMEI1060 BAB1_0927 BR0909 0.763 DsbA Protein-disulfide isomerase
BMEI0324 BAB1_1726 BR1714 0.822 COG1360 Flagellar Motor Protein
BMEI0039 BAB1_2033 BR2032 0.700 Acetyl CoA carboxylase,
carboxyltransferase, alpha subunit
BMEI0503 BAB1_1528 BR1510 0.865 COG1607 Acyl-CoA Hydrolase
Serodiagnostic for
Goats only
BMEII0988 BAB2_0943 BRA0260 0.942 Copper-containing nitrite reductase
NirK
BMEII0601 BAB2_0558 BRA0682 0.917 ABC amino acid transporter,
periplasmic binding protein
BMEII0073 BAB2_0019 BRA0020 1.000 Hypothetical protein
BMEI0668 BAB2_0441 BRA0797 1.000 Calcium binding protein Asp24 {Lin, 1995}
BMEII0734 BAB2_0699 BRA0538 0.983 Oligopeptide binding protein
precursor
BMEI0796 BAB1_0294 BR0263 0.950 TRAP transporter solute receptor
Bcsp31
{Mayfield, 1988}
BMEII0217 BAB2_1043 BRA1084 0.908 ABC dipeptide transport protein,
periplasmic component
BMEI1725 BAB1_0226 BR0225 0.967 COG1732 glycine betaine-binding
protein
BMEII1047 BAB2_0190 BRA0196 0.967 10kDa chaperonin groES {Connolly, 2006}
BMEI2053 BAB1_2075 BR2074 0.892 Calcium binding protein
BMEI0178 BAB1_1885 BR1885 0.967 Hypothetical protein
BMEI0991 BAB1_1009 BR0990 0.842 Rare Lipoprotein A
BMEII0338 BAB2_0275 BRA0960 0.958 ABC transporter periplasmic
BP, lipoprotein
BMEII0573 BAB2_0527 BRA0712 0.917 Transcriptional regulator, RpiR
family
BMEII0179 BAB2_1078 BRA1120 0.858 Zn binding protein
BMEII0859 BAB2_0812 BRA0409 0.883 ABC dipeptide transport system,
periplasmic component
doi:10.1371/journal.pntd.0000673.t001
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Discussion
Here we report a large scale analysis showing that the humoral
immune responses against B. melitensis protein antigens differ
between humans naturally infected by consuming Brucella melitensis-
contaminated, unpasteurized goat’s milk products, and goats
experimentally infected with B. melitensis by conjunctival instilla-
tion. These observations show that a natural reservoir host and the
accidental human host have fundamentally different immune
responses against this zoonotic pathogen. These data have
implications for the practical development of diagnostics and
reflect basic differences in host pathogen interactions and disease
pathogenesis.
In addition, we demonstrate that a systematic, genome-wide
analysis proved to identify protein antigens recognized by humans
and animals not previously identified using Western blot or
genomic library immunoscreening. Further, by virtue of being
found to react with antibodies, the protein array technology is
able to provide strong evidence of the comprehensive set of
proteins expressed in vivo within a mammalian host by B. melitensis.
As with our published experience with viral, bacterial and pro-
tozoal genomes expressed using protein microarray technology
[44,49,50,58,64–66], conformation-dependent epitopes seem not
to present problems with data interpretation or comprehensiveness
of antigen discovery. This is likely because the polyclonal antibody
response to protein antigens after infection detects both linear and
3-dimensional epitopes. The B. melitensis proteins placed onto the
array, while expressed heterologously in a bacterial system, likely
reflect a mix of conformationally correct as well as misfolded
epitopes both of which are capable of binding specific antibodies.
Serological diagnosis of both human and animal brucellosis can
suffer from the inability to distinguish new from previous infection
(in the case of humans [1]) and differentiation of vaccination from
new infection (in the case of animals [8]). In the absence of known
exposure history in endemic regions, there is the possibility of
mistaken diagnosis and overtreatment [10]. Current assays are
based primarily on identification of antibodies to LPS in patient
serum. Since Brucella LPS is cross-reactive with several other
species, including E. coli O157:H7, Yersinia enterocolitica O9, and
Francisella tularensis (although the clinical presentations of infectious
caused by these agents are quite different), identification of
diagnostic protein antigens may facilitate the development of more
specific serodiagnostic assays [21,67,68]. The top 5 serodiagnostic
antigens discovered using the protein microarrays had sensitivity
and specificity of 95% and 96%, better than that of the 13 antigens
on the immunostrips (94% and 89%), which in turn was roughly
comparable to that of smooth LPS-based tests used in the Rose
Bengal, lateral flow, and ELISA formats. In the present study
however, the sensitivity of the serodiagnostic protein antigens
could not be compared to that of the Rose Bengal test because we
did not confirm any brucellosis cases among Rose Bengal negative
patients by culture.
One interesting finding of this study was the difference in
background reactivity to B. melitensis proteins in uninfected
individuals from endemic vs. non-endemic areas. In Peru, control
subjects tended to have higher background reactivity to Brucella
antigens, compared to US control subjects (Fig. 3a). Consideration
of these differences would be important for the development of
diagnostic assays intended for use in both endemic and non-
endemic regions of the world. The degree of variability between
subjects differs depending on the infection and the results for
Brucella reported here are similar to those that we obtained from
patients with melioidosis [64,65] and Lyme disease.
Figure 5. Immunostrips probing. (a)Thirteen serodiagnostic anti-
gens were printed onto nitrocellulose paper in adjacent stripes using a
BioDot jet dispenser as described in Materials and Methods. Strips were
probed with Culture Positive or Peruvian naive sera diluted 1/200
followed by alkaline phosphatase conjugated secondary antibody and
enzyme substrate. Weak reactivity in the naı¨ve healthy controls can be
distinguished from the strong reactivity in infected group. (b). The
LOOCV ROC curve was generated and sensitivity and specificity of
immunostrips probing test is 94% and 89%, respectively.
doi:10.1371/journal.pntd.0000673.g005
Figure 6. Serodiagnostic and cross-reactive antigens for
humans and goats.
doi:10.1371/journal.pntd.0000673.g006
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Our results with the B. melitensis proteome array represent the
first large-scale analysis of B. melitensis proteins that are
immunogenic in the context of naturally acquired human
infections. In the case of the present study, the identified risk
factor for human infection was ingestion of B. melitensis-
contaminated, unpasteurized goat’s milk products. In other
epidemiological contexts, B. melitensis can be contracted by direct
exposure to infected animals, not only goats, but also sheep and
cattle [1,3]. Further, we compared the set of proteins identified
using human patient sera with the set that was immunogenic in the
animal reservoir for zoonotic disease, the goat. Two proteins,
BMEI0536 (Bp26) and BMEI1330 (HtrA/DegP), were immuno-
genic in the context of both infections. These results are in good
agreement with previous reports on these antigens from other
Brucella spp. Roop et al. [31] showed that HtrA was recognized by
serum from goats, cattle and mice experimentally infected with B.
abortus and by serum of dogs infected with B. canis. HtrA/DegP is a
periplasmic serine protease that contributes to survival following
stresses including oxidative damage. Bp26 has been proposed as a
diagnostic antigen for detection of B. melitensis infection in sheep
and B. abortus in cattle [17,19]. The Omp16 lipoprotein
(BMEI0340), originally identified as an immunogenic protein of
B. abortus [32], was recognized by patient sera, but was found to be
reactive in both infected and uninfected goats. Our results differ
from those of Letesson et al., who reported no reactivity of
uninfected goats to Omp16 [25]. This difference may reflect
exposure of goats used in our study to other pathogens or to
environmental bacteria expressing a cross-reactive antigen. The
identification of known immunogenic Brucella proteins on the
proteome array provided confirmation that our approach could
identify both known and novel immunogenic proteins.
In addition to these well-characterized antigens, our study
identified several novel serodiagnostic antigens specific for human
B. melitensis patients (Table 1). These included BMEI1439 (SMC),
an ATPase shown in other bacterial species to be involved in
condensation and segregation of replicating chromosomes [29].
Further, the bacterial cell envelope proteins VirB8 (BMEII0032),
DsbA (BMEI1060), and an uncharacterized transporter
(BMEI1890), were immunogenic in patients. Three metabolic
enzymes, acetyl coA carboxylase, (BMEI0503), Acetyl CoA
carboxylase (BMEI0039 and 2-oxoglutarate dehydrogenase
(BMEI0141) also represent novel serodiagnostic antigens for
human brucellosis. The finding that these proteins are immuno-
genic suggests that they are expressed during B. melitensis infection
of humans.
A group of 16 antigens was found to be serodiagnostic for goats,
but not humans (Table 1). These included 7 predicted transport-
ers, as well as a zinc-binding protein and two binding proteins for
calcium: Asp24 (BMEI0668) [26], and a second, uncharacterized
Table 2. Cross-reactive Brucella melitensis antigens for
humans and goats.
B. melitensis Product Name
Cross- reactive
for both Humans
and Goats
BMEI1079 Lipoprotein NlpD
BMEII0154 Flagellar motor protein
BMEI0613 Protease Do
BMEI1073 Glucose-inhibited division protein A
BMEII0497 Enoyl-CoA hydratase/3-hydroxyacyl-
CoA dehydrogenase
BMEI0063 Hypothetical membrane spanning
protein
BMEII0010 Hypothetical membrane associated
protein
BMEI0847 Protein-export membrane protein
Cross- reactive
for Humans only
BMEI0179 Hypothetical protein transporter
BMEI2053
BMEI1646 Acriflavin resistance protein E
BMEI1471 4-Amino-4-deoxychorismate lyase
BMEI1236 Hypothetical exported proline-rich
protein
BMEI1692 Flagellar protein FlgJ
BMEII0571 Acetolactate synthase IolD
BMEII0793 Multidrug resistance efflux pump
BMEI0123 Peptidyl-prolyl cis-trans isomerase
BMEII0019 Stomatin like protein
BMEII1118 Multidrug resistance protein A
BMEI0848 Probable carnitine operon
oxidoreductase CaiA
Cross-reactive
for Goats only
BMEI1989 Phosphate-binding periplasmic protein
periplasmic oligopeptide-binding
protein precursor
BMEII0735
BMEI0263 Leu-, Ile-, Val-, Thr-, and Ala-binding
protein precursor
BMEI1792 Hypothetical protein
BMEII0381 Acriflavin resistance protein E
BMEI0475 Cytochrome C1
BMEI0053 Cation-transporting ATPase PacS
BMEII1111 Hypothetical protein
BMEI0443 Hypothetical protein
BMEI1439 Chromosome segregation protein
SMC2
BMEI0340 Peptidoglycan-associated lipoprotein
Omp16
BMEI1954 ABC transporter substrate binding
protein
BMEII0678 Lipoyltransferase
BMEI1334 Cytochrome C-type biogenesis protein
CycH
BMEI1280 Hypothetical cytosolic protein
BMEI0749 DNA-directed RNA polymerase beta
subunit
BMEII0029 Type IV secretion apparatus protein
VirB5
B. melitensis Product Name
BMEI1000 Hypothetical protein
BMEI0821 Hypothetical protein
BMEII0852 Succinoglycan biosynthesis transport
protein
BMEI1060 DsbA Protein-disulfide isomerase
BMEI1428 Ribonuclease III
BMEII0151 Flagellar Mring protein FliF
doi:10.1371/journal.pntd.0000673.t002
Table 2. Cont.
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calcium-binding protein (BMEI2053). The chaperonin GroES,
shown to be seroreactive in a patient suffering from B. suis
infection [20], was serodiagnostic in goats, as well as Bscp31
(BMEI0796), a well-known seroreactive protein [28].
The differences in the patterns of goat and human seroreactivity
to B. melitensis proteins could be explained in several different ways.
First, the group of seroreactive proteins in goats and humans gives
some insight into the metabolic pathways expressed during
infection in these hosts. The large number of immunogenic
proteins with predicted function in nutrient uptake suggests that B.
melitensis utilizes peptides and amino acids for growth during
infection. Three serodiagnostic B. melitensis proteins (BMEI0340,
BMEI0141 and BMEI0178), have been found to be upregulated
during intracellular infection by B. suis or B. abortus [18,24],
suggesting that they may play a role in adaptation to intracellular
life in the host. Second, the immunogenetics of immune responses
to B. melitensis infection may be related to species differences
between humans and goats but further comment on this possibility
is limited by the lack of available data. Third, while humans in this
study were thought to have been infected by ingestion of infected
goat’s milk products containing a small inoculum, the goats were
infected with a high dose (107 CFU) of B. melitensis strain 16M via
the conjunctiva. Both dose and route of inoculum may have
contributed to the differential antigen recognition between goats
and humans, and, in fact, among humans as well. Finally, while it
seems unlikely that the different patterns of immune response
variation between goats and humans were due to protein
expression differences by different strains of B. melitensis, this
possibility must be considered as well.
The results presented here represent an analysis of 1406
proteins of 3198 predicted proteins in the B. melitensis 16M
genome. Of these 1406 proteins, we only observed less than two
fold enrichment of serodiagnostic antigens in the 1009 selected
versus randomly selected antigens (not shown). Completion of the
proteome array is currently underway, which will allow a more
complete genome-level analysis of all immunogenic B. melitensis
proteins. The subset of diagnostic antigens identified here
provided an initial estimated accuracy rate of 95% for diagnosis
of human cases and it is likely that this set of antigens will form the
basis of a new and accurate serodiagnostic assay for human
brucellosis. The clinical and veterinary utility of the protein
antigens discovered in this study for diagnosis of acute and chronic
brucellosis awaits validation in prospective studies in endemic
regions.
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